News - September 15, 2023
On 12 September 2023, the European Parliament adopted the report on new rules governing the use of so-called substances of human origin (SoHO) intended for human application. The Council still needs to adopt its official position, with the Spanish Presidency hoping to kick off Trilogues… read more
News / Press Releases - September 6, 2023
6 September 2023, Brussels – EUCOPE, as part of a multi-stakeholder group consisting of 32 European patient organisations, medical associations, research organisations, data collaborations and industry associations met EU officials, including MEP Tomislav Sokol, Co-Rapporteur, as well as several permanent representations that will hold upcoming… read more
Job Posting / News - August 24, 2023
We are looking to recruit a dynamic and experienced Communications and Business Development Manager to lead and implement our internal and external communication strategies while developing new membership and partnership opportunities for the organisation. ROLE & RESPONSIBILITIES Responsible for the overall communications activities of EUCOPE,… read more
Member Spotlight - August 22, 2023
Every month, EUCOPE spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In August, we spoke with Shekhar Natarajan, Vice President – EU Regulatory Affairs, Dyne Therapeutics. Shekhar Natarajan is Vice President-… read more
News - August 18, 2023
EUCOPE’s Sounds of Science Podcast – Episode 17 Real-World Evidence (RWE): The need for a multi-stakeholder approach Within the EU, the life sciences industry requires a strong innovation framework across the patient journey so that such technological advancements can be used to the benefit of… read more
News - July 21, 2023
On 18 July, European lawmakers within the Health and Environment (ENVI) committee voted to adopt the amended report on Substances of Human Origin (SoHo). The report aims to improve the safety and quality standards for both donors and recipients of blood, plasma, skin, embryo, sperm,… read more
EUCOPE Resources / News - July 14, 2023
On 7 July, EUCOPE – the European Confederation of Pharmaceutical Entrepreneurs – hosted the second episode of its Life Science Lectures webinar series. The focus of the webinar, titled ‘’Defining (high) unmet medical need: will it steer innovation towards filling existing gaps?’’, was to dive… read more
EUCOPE Resources / News / Press Releases - July 13, 2023
On 12 July 2023, EUCOPE’s HERA Steering Group released its White Paper “EU-wide Stockpiling: Better Preparedness for Cross-Border Health Threats.” Stockpiling of critical biomedical countermeasures is crucial for an effective EU preparedness against priority cross-border health threats with a potentially large health and societal impact…. read more
EUCOPE Resources / News - July 12, 2023
EUCOPE’S Sounds of Science Podcast – Episode 16 Rare Reflections: Impact of the OMP revision on rare disease companies in Europe On 26 April 2023, the European Commission published its long awaited proposal revising the foundational pharmaceutical legislation, including the Orphan Medicinal Products (OMP) Regulation…. read more
Member Spotlight / News / Press Releases - June 29, 2023
The European Confederation of Pharmaceuticals Entrepreneurs (EUCOPE) announced the joining of six (6) new members at its quarterly Members Meeting on June 21st, 2023 following Board approval. The new members joining EUCOPE network are Azafaros, Deciphera Pharmaceuticals, Dyne Therapeutics, HemaNext, MediWound and Rocket Pharmaceuticals. During… read more
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information